A Randomized Phase II Trial Comparing NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer
Latest Information Update: 27 Oct 2022
Price :
$35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Nippon Kayaku
- 24 Nov 2021 Status changed from recruiting to completed.
- 22 Mar 2018 Status changed from not yet recruiting to recruiting.
- 22 Feb 2018 New trial record